Log in to search using one of your social media accounts:

 

Outcomes and Mutational Analysis of a Prospective Phase II Trial of Azacitidine in Patients with MDS and AML with Early Post-Transplant Relapse

Post-transplant relapse remains a major cause of treatment failure in patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Understanding of the biology of relapse and response to azacitidine treatment remains limited.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

Allogeneic hematopoietic stem cell transplantation (AHSCT) is a successful treatment modality for AML and MDS. Information on transplant outcomes among older patients is limited because of concern of adverse transplant-related mortality (TRM) and poor overall survival (OS).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Hematopoietic cell transplantation (HCT) is a potentially curative treatment for patients with high-risk hematologic malignancies [1,2]. Common indications for HCT in adults include acute myelogenous leukemia, myeloproliferative neoplasms, myelodysplastic syndromes, chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, lymphoma, multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, and certain solid tumors [2].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Conclusion SDF-1/CXCR4 axis plays a crucial role in engraftment; however, more studies are warranted to assess their expression post-transplant. Evaluating the ligand (chemokine, SDF-1) or its receptor (CXCR4) may serve as potential surrogate markers for assessment of engraftment.
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: The Delphi method was useful for the classification and stratification of risk factors for IFI-FF in patients with onco-haematological diseases. Identifying key risk factors will contribute to a better management of IFI-FF in this group of patients at high or changing risk. PMID: 28198173 [PubMed - as supplied by publisher]
Source: Revista Espanola de Quimioterapia - Category: Drugs & Pharmacology Authors: Tags: Rev Esp Quimioter Source Type: research
To retrospectively analyze the outcome of patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) early relapsing after HSCT.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative approach for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Since azacitidine approval for the treatment of high-risk MDS and low-blast count AML, patients experienced reduction of therapy-related complications and satisfactory overall response rate.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Conclusion MDS is rare and tends to be more aggressive in the AYA population. Karyotype was the most important prognostic factor. Allogeneic stem-cell transplantation offered younger patients the best outcomes. Micro-Abstract Little is known regarding myelodysplastic syndromes (MDS) in the younger population. This retrospective review reviewed the characteristics, outcomes, and response to treatment in the adolescent and young adult (AYA) population compared to an older population. MDS was found to be rare and more aggressive in AYA. Karyotype was the most important prognostic factor. Allogeneic stem-cell transplantation o...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
CONCLUSION: MDS is rare and tends to be more aggressive in the AYA population. Karyotype was the most important prognostic factor. Allogeneic stem-cell transplantation offered younger patients the best outcomes. PMID: 27521325 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Lymphoma Myeloma Leuk Source Type: research
Conclusion We conclude that the use of fresh cells versus cryopreserved cells does not have an impact on outcomes, and selected patients can achieve long-term survival with DLI for treatment of relapse after transplantation, although the overall outcomes remain dismal. Micro-Abstract Since its initial application in chronic myelogenous leukemia (CML), donor lymphocyte infusion (DLI) has been applied to various hematologic malignancies with varied success. A recent trend has been the shift from using fresh cells to cryopreserved cells. In a retrospective analysis of 63 patients, we found that there was no difference in out...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion The development of t-MN in patients with MM is associated with poor outcomes. These patients, in general, have complex cytogenetic abnormalities and short complete remission and OS times. A better understanding of the disease biology and novel therapeutic approaches are warranted. Micro-Abstract During the past decade, the survival of patients with multiple myeloma (MM) has significantly improved. However, the risk of a therapy-related myeloid neoplasm (t-MN) is increased in patients with MM. The outcomes for these patients once they have developed t-MNs are very poor, with survival measured in months. The expl...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Biology | Leukemia | Lymphoma | Myelodysplastic Syndrome | Myeloma | Transplants